GRAIL Investor Relations Material
Latest events
Q1 2025
GRAIL
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from GRAIL
Access all reports
GRAIL, Inc. is a biotechnology company specializing in the development of advanced technologies for early cancer detection. The company's primary product is the Galleri test, a multi-cancer early detection test designed to screen for a wide range of cancers, particularly those without current recommended screenings. In addition to Galleri, GRAIL is also working on diagnostic aids and minimal residual disease tests to assist in the detection and monitoring of cancer. The company is headquartered in Menlo Park, California, and its shares are listed on the Nasdaq.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
GRAL
Country
🇺🇸 United States